Annual Total Long Term Liabilities
$69.52 M
+$3.15 M+4.74%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual total long term liabilities is currently $69.52 million, with the most recent change of +$3.15 million (+4.74%) on 31 December 2023. During the last 3 years, it has fallen by -$483.13 million (-87.42%). LGND annual total long term liabilities is now -90.22% below its all-time high of $710.68 million, reached on 31 December 2019.LGND Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$88.92 M
+$16.27 M+22.40%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly total long term liabilities is currently $88.92 million, with the most recent change of +$16.27 million (+22.40%) on 30 September 2024. Over the past year, it has increased by +$3.31 million (+3.87%). LGND quarterly long term liabilities is now -87.49% below its all-time high of $710.68 million, reached on 31 December 2019.LGND Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +4.7% | +3.9% |
| 3 y3 years | -87.4% | -79.1% |
| 5 y5 years | -88.7% | -86.5% |
LGND Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -87.4% | +4.7% | -79.5% | +39.3% |
| 5 y | 5 years | -90.2% | +4.7% | -87.5% | +39.3% |
| alltime | all time | -90.2% | +1987.7% | -87.5% | +3941.6% |
Ligand Pharmaceuticals Incorporated Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $88.92 M(+22.4%) |
| June 2024 | - | $72.64 M(-18.9%) |
| Mar 2024 | - | $89.53 M(+28.8%) |
| Dec 2023 | $69.52 M(+4.7%) | $69.52 M(-18.8%) |
| Sept 2023 | - | $85.60 M(+34.1%) |
| June 2023 | - | $63.83 M(-3.0%) |
| Mar 2023 | - | $65.83 M(-0.8%) |
| Dec 2022 | $66.37 M(-84.7%) | $66.37 M(-33.0%) |
| Sept 2022 | - | $99.07 M(-6.6%) |
| June 2022 | - | $106.07 M(-60.6%) |
| Mar 2022 | - | $269.41 M(-38.0%) |
| Dec 2021 | $434.77 M(-21.3%) | $434.77 M(+2.2%) |
| Sept 2021 | - | $425.29 M(+1.9%) |
| June 2021 | - | $417.27 M(-8.0%) |
| Mar 2021 | - | $453.48 M(-17.9%) |
| Dec 2020 | $552.65 M(-22.2%) | $552.65 M(+8.9%) |
| Sept 2020 | - | $507.32 M(-2.2%) |
| June 2020 | - | $518.67 M(+3.0%) |
| Mar 2020 | - | $503.58 M(-29.1%) |
| Dec 2019 | $710.68 M(+15.1%) | $710.68 M(+7.5%) |
| Sept 2019 | - | $661.20 M(+1.5%) |
| June 2019 | - | $651.40 M(+0.6%) |
| Mar 2019 | - | $647.24 M(+4.8%) |
| Dec 2018 | $617.64 M(+4473.1%) | $617.64 M(+0.8%) |
| Sept 2018 | - | $612.88 M(+1.2%) |
| June 2018 | - | $605.62 M(+5661.8%) |
| Mar 2018 | - | $10.51 M(-22.2%) |
| Dec 2017 | $13.51 M(+274.9%) | $13.51 M(+129.3%) |
| Sept 2017 | - | $5.89 M(+23.4%) |
| June 2017 | - | $4.78 M(+20.9%) |
| Mar 2017 | - | $3.95 M(+9.6%) |
| Dec 2016 | $3.60 M(+8.2%) | $3.60 M(-17.0%) |
| Sept 2016 | - | $4.34 M(-4.3%) |
| June 2016 | - | $4.54 M(-97.8%) |
| Mar 2016 | - | $209.12 M(+6179.9%) |
| Dec 2015 | $3.33 M(-98.4%) | $3.33 M(-98.4%) |
| Sept 2015 | - | $213.27 M(-2.1%) |
| June 2015 | - | $217.76 M(+2.4%) |
| Mar 2015 | - | $212.67 M(+0.9%) |
| Dec 2014 | $210.84 M(+705.9%) | $210.84 M(-0.1%) |
| Sept 2014 | - | $211.07 M(+1063.5%) |
| June 2014 | - | $18.14 M(-6.8%) |
| Mar 2014 | - | $19.46 M(-25.6%) |
| Dec 2013 | $26.16 M(-38.2%) | $26.16 M(+7.2%) |
| Sept 2013 | - | $24.40 M(-12.0%) |
| June 2013 | - | $27.73 M(-20.2%) |
| Mar 2013 | - | $34.75 M(-17.9%) |
| Dec 2012 | $42.34 M(-38.4%) | $42.34 M(-8.7%) |
| Sept 2012 | - | $46.39 M(-16.7%) |
| June 2012 | - | $55.72 M(-14.7%) |
| Mar 2012 | - | $65.35 M(-5.0%) |
| Dec 2011 | $68.75 M(+46.5%) | $68.75 M(-11.4%) |
| Sept 2011 | - | $77.64 M(-2.7%) |
| June 2011 | - | $79.79 M(-5.7%) |
| Mar 2011 | - | $84.57 M(+80.3%) |
| Dec 2010 | $46.92 M(-45.4%) | $46.92 M(-45.0%) |
| Sept 2010 | - | $85.33 M(+4.9%) |
| June 2010 | - | $81.34 M(-9.7%) |
| Mar 2010 | - | $90.04 M(+4.8%) |
| Dec 2009 | $85.89 M | $85.89 M(+16.8%) |
| Sept 2009 | - | $73.54 M(-21.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2009 | - | $93.23 M(-8.1%) |
| Mar 2009 | - | $101.40 M(-8.8%) |
| Dec 2008 | $111.20 M(+19.3%) | $111.20 M(+18.9%) |
| Sept 2008 | - | $93.54 M(-3.0%) |
| June 2008 | - | $96.39 M(-1.1%) |
| Mar 2008 | - | $97.42 M(+4.5%) |
| Dec 2007 | $93.19 M(-27.1%) | $93.19 M(-25.7%) |
| Sept 2007 | - | $125.40 M(-0.6%) |
| June 2007 | - | $126.19 M(+10.1%) |
| Mar 2007 | - | $114.56 M(-10.4%) |
| Dec 2006 | $127.89 M(-32.6%) | $127.89 M(-50.2%) |
| Sept 2006 | - | $256.64 M(+0.2%) |
| June 2006 | - | $256.02 M(-0.4%) |
| Mar 2006 | - | $257.02 M(+35.4%) |
| Dec 2005 | $189.83 M(-0.7%) | $189.83 M(-0.0%) |
| Sept 2005 | - | $189.87 M(-0.4%) |
| June 2005 | - | $190.63 M(-0.2%) |
| Mar 2005 | - | $190.99 M(-0.0%) |
| Dec 2004 | $191.07 M(-0.4%) | $191.07 M(+8.5%) |
| Sept 2004 | - | $176.17 M(+0.2%) |
| June 2004 | - | $175.85 M(-0.4%) |
| Mar 2004 | - | $176.56 M(-8.0%) |
| Dec 2003 | $191.89 M(+15.6%) | $191.89 M(+17.1%) |
| Sept 2003 | - | $163.91 M(-0.5%) |
| June 2003 | - | $164.72 M(-0.4%) |
| Mar 2003 | - | $165.33 M(-0.4%) |
| Dec 2002 | $166.06 M(+15.6%) | $166.06 M(+1603.0%) |
| Sept 2002 | - | $9.75 M(+8.8%) |
| June 2002 | - | $8.96 M(-6.3%) |
| Mar 2002 | - | $9.57 M(-93.3%) |
| Dec 2001 | $143.62 M(+2.5%) | $143.62 M(-0.3%) |
| Sept 2001 | - | $144.10 M(-0.5%) |
| June 2001 | - | $144.87 M(+2.3%) |
| Mar 2001 | - | $141.60 M(+1.0%) |
| Dec 2000 | $140.13 M(+0.5%) | $140.13 M(+14.0%) |
| Sept 2000 | - | $122.90 M(+1.2%) |
| June 2000 | - | $121.42 M(+1.3%) |
| Mar 2000 | - | $119.81 M(-14.1%) |
| Dec 1999 | $139.50 M(-0.7%) | $139.50 M(-11.4%) |
| Sept 1999 | - | $157.50 M(+18.6%) |
| June 1999 | - | $132.80 M(+1.3%) |
| Mar 1999 | - | $131.10 M(-6.7%) |
| Dec 1998 | $140.50 M(+173.3%) | $140.50 M(+40.9%) |
| Sept 1998 | - | $99.70 M(+103.9%) |
| June 1998 | - | $48.90 M(-6.3%) |
| Mar 1998 | - | $52.20 M(+1.6%) |
| Dec 1997 | $51.40 M(-4.5%) | $51.40 M(+3.6%) |
| Sept 1997 | - | $49.60 M(-3.9%) |
| June 1997 | - | $51.60 M(+1.6%) |
| Mar 1997 | - | $50.80 M(-5.6%) |
| Dec 1996 | $53.80 M(+8.0%) | $53.80 M(+12.1%) |
| Sept 1996 | - | $48.00 M(-6.6%) |
| June 1996 | - | $51.40 M(+1.6%) |
| Mar 1996 | - | $50.60 M(+1.6%) |
| Dec 1995 | $49.80 M(+304.9%) | $49.80 M(+0.4%) |
| Sept 1995 | - | $49.60 M(+313.3%) |
| Mar 1995 | - | $12.00 M(-2.4%) |
| Dec 1994 | $12.30 M | $12.30 M(0.0%) |
| Sept 1994 | - | $12.30 M(+412.5%) |
| June 1994 | - | $2.40 M(+9.1%) |
| Mar 1994 | - | $2.20 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual total long term liabilities?
- What is the all time high annual total long term liabilities for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual total long term liabilities year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly long term liabilities year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual total long term liabilities?
The current annual total long term liabilities of LGND is $69.52 M
What is the all time high annual total long term liabilities for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual total long term liabilities is $710.68 M
What is Ligand Pharmaceuticals Incorporated annual total long term liabilities year-on-year change?
Over the past year, LGND annual total long term liabilities has changed by +$3.15 M (+4.74%)
What is Ligand Pharmaceuticals Incorporated quarterly total long term liabilities?
The current quarterly long term liabilities of LGND is $88.92 M
What is the all time high quarterly long term liabilities for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly total long term liabilities is $710.68 M
What is Ligand Pharmaceuticals Incorporated quarterly long term liabilities year-on-year change?
Over the past year, LGND quarterly total long term liabilities has changed by +$3.31 M (+3.87%)